Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RVU120 Monotherapy and in Combination With Ruxolitinib in Myelofibrosis
NCT06397313Phase 2Terminated
- Sponsor
- Ryvu Therapeutics
- Start
- Sep 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of rvu120 in myelofibrosis (MF), sponsored by Ryvu Therapeutics. Started Sep 2024; status: terminated.
02
Drugs
rvu120
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT06397313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06397313.